Intelligent nanomaterials for cancer therapy: recent progresses and future possibilities
Author:
Wang Jing12ORCID, Zhao Yuliang13ORCID, Nie Guangjun123ORCID
Affiliation:
1. CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center of Excellence in Nanoscience, National Center for Nanoscience and Technology , Beijing , China 2. Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences , Beijing , China 3. GBA Research Innovation Institute for Nanotechnology , Guangzhou , Guangdong Province , China
Abstract
Abstract
Intelligent nanomedicine is currently one of the most active frontiers in cancer therapy development. Empowered by the recent progresses of nanobiotechnology, a new generation of multifunctional nanotherapeutics and imaging platforms has remarkably improved our capability to cope with the highly heterogeneous and complicated nature of cancer. With rationally designed multifunctionality and programmable assembly of functional subunits, the in vivo behaviors of intelligent nanosystems have become increasingly tunable, making them more efficient in performing sophisticated actions in physiological and pathological microenvironments. In recent years, intelligent nanomaterial-based theranostic platforms have showed great potential in tumor-targeted delivery, biological barrier circumvention, multi-responsive tumor sensing and drug release, as well as convergence with precise medication approaches such as personalized tumor vaccines. On the other hand, the increasing system complexity of anti-cancer nanomedicines also pose significant challenges in characterization, monitoring and clinical use, requesting a more comprehensive and dynamic understanding of nano-bio interactions. This review aims to briefly summarize the recent progresses achieved by intelligent nanomaterials in tumor-targeted drug delivery, tumor immunotherapy and temporospatially specific tumor imaging, as well as important advances of our knowledge on their interaction with biological systems. In the perspective of clinical translation, we have further discussed the major possibilities provided by disease-oriented development of anti-cancer nanomaterials, highlighting the critical importance clinically-oriented system design.
Publisher
Walter de Gruyter GmbH
Reference180 articles.
1. Wang, J, Li, Y, Nie, G. Multifunctional biomolecule nanostructures for cancer therapy. Nat Rev Mater 2021;6:766–83. https://doi.org/10.1038/s41578-021-00315-x. 2. Shi, J, Kantoff, PW, Wooster, R, Farokhzad, OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 2016;17:20. https://doi.org/10.1038/nrc.2016.108. 3. Chen, H, Zhang, W, Zhu, G, Xie, J, Chen, X. Rethinking cancer nanotheranostics. Nat Rev Mater 2017;2:17024. https://doi.org/10.1038/natrevmats.2017.24. 4. Nam, J, Son, S, Park, KS, Zou, W, Shea, LD, Moon, JJ. Cancer nanomedicine for combination cancer immunotherapy. Nat Rev Mater 2019;4:398–414. https://doi.org/10.1038/s41578-019-0108-1. 5. Schroeder, A, Heller, DA, Winslow, MM, Dahlman, JE, Pratt, GW, Langer, R, et al.. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2012;12:39–50. https://doi.org/10.1038/nrc3180.
|
|